First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 ...
Both were derivative-based transactions involving the conversion of Series B shares into Series A shares, which were then sold directly in the open market. Is the timing or size of these sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results